Clearside Biomedical, Inc. (CLSD): Price and Financial Metrics

Clearside Biomedical, Inc. (CLSD): $1.04

0.08 (+8.67%)

POWR Rating

Component Grades














  • Sentiment is the dimension where CLSD ranks best; there it ranks ahead of 89.56% of US stocks.
  • CLSD's strongest trending metric is Growth; it's been moving down over the last 177 days.
  • CLSD ranks lowest in Stability; there it ranks in the 22nd percentile.

CLSD Stock Summary

  • CLSD's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.02 -- higher than only 0.66% of US-listed equities with positive expected earnings growth.
  • With a year-over-year growth in debt of 5,124%, CLEARSIDE BIOMEDICAL INC's debt growth rate surpasses 99.38% of about US stocks.
  • Over the past twelve months, CLSD has reported earnings growth of -8,862.5%, putting it ahead of merely 0.26% of US stocks in our set.
  • Stocks that are quantitatively similar to CLSD, based on their financial statements, market capitalization, and price volatility, are CLGN, SLDP, SLGL, EFTR, and DCPH.
  • Visit CLSD's SEC page to see the company's official filings. To visit the company's web site, go to

CLSD Valuation Summary

  • In comparison to the median Healthcare stock, CLSD's price/earnings ratio is 107.76% lower, now standing at -1.8.
  • CLSD's price/earnings ratio has moved up 5.5 over the prior 83 months.

Below are key valuation metrics over time for CLSD.

Stock Date P/S P/B P/E EV/EBIT
CLSD 2023-03-24 44.8 5.6 -1.8 -1.4
CLSD 2023-03-23 47.2 5.9 -1.9 -1.5
CLSD 2023-03-22 46.7 5.8 -1.9 -1.5
CLSD 2023-03-21 47.2 5.9 -1.9 -1.5
CLSD 2023-03-20 44.9 5.6 -1.8 -1.4
CLSD 2023-03-17 48.1 6.0 -1.9 -1.5

CLSD Growth Metrics

    Its 5 year net cashflow from operations growth rate is now at 41.22%.
  • Its year over year net cashflow from operations growth rate is now at 91.79%.
  • The 5 year price growth rate now stands at -77.53%.
CLSD's revenue has moved up $24,511,000 over the prior 33 months.

The table below shows CLSD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 26.684 -2.704 -4.575
2022-06-30 29.492 0.204 -1.635
2022-03-31 29.888 -1.303 0.083
2021-12-31 29.575 -10.733 0.376
2021-09-30 3.899 -20.223 -25.445
2021-06-30 4.257 -19.606 -22.991

CLSD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CLSD has a Quality Grade of C, ranking ahead of 52.15% of graded US stocks.
  • CLSD's asset turnover comes in at 0.183 -- ranking 206th of 681 Pharmaceutical Products stocks.
  • GLYC, MDVL, and XENE are the stocks whose asset turnover ratios are most correlated with CLSD.

The table below shows CLSD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.183 1 3.825
2021-03-31 0.186 1 3.961
2020-12-31 0.397 1 3.928
2020-09-30 0.452 1 4.357
2020-06-30 0.274 1 13.716
2020-03-31 0.232 1 -11.517

CLSD Price Target

For more insight on analysts targets of CLSD, see our CLSD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $11.60 Average Broker Recommendation 1.58 (Moderate Buy)

CLSD Stock Price Chart Interactive Chart >

Price chart for CLSD

CLSD Price/Volume Stats

Current price $1.04 52-week high $2.54
Prev. close $0.96 52-week low $0.90
Day low $0.98 Volume 189,900
Day high $1.05 Avg. volume 202,373
50-day MA $1.24 Dividend yield N/A
200-day MA $1.33 Market Cap 63.82M

Clearside Biomedical, Inc. (CLSD) Company Bio

Clearside Biomedical, a biopharmaceutical company, develops drug therapies to treat chronic blinding diseases of the eye. The company was founded in 2011 and is based in Alpharetta, Georgia

CLSD Latest News Stream

Event/Time News Detail
Loading, please wait...

CLSD Latest Social Stream

Loading social stream, please wait...

View Full CLSD Social Stream

Latest CLSD News From Around the Web

Below are the latest news stories about CLEARSIDE BIOMEDICAL INC that investors may wish to consider to help them evaluate CLSD as an investment opportunity.

Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2022 Earnings Call Transcript

Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2022 Earnings Call Transcript March 9, 2023 Operator: Good day and thank you for standing by and welcome to the Clearside Biomedical Fourth Quarter 2022 Financial Results and Corporate Update Conference Call. At this time all participants are in a listen-only mode. After the speakers’ presentation there will be a […]

Yahoo | March 11, 2023

Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -23.08% and 111.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | March 9, 2023

Clearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

- Initiation of Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected in Q2 2023 - - Medical Meeting Presentations Highlight Significant Potential of CLS-AX Based on Positive OASIS Phase 1/2a Safety Data, Durability, and Biologic Effect Over 6 Months - - Continued Growth in Retinal Specialists Trained in Suprachoroidal Space (SCS®) Injection Procedure Using FDA-Approved XIPERE® - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., March 09, 2023 (GLOBE NEWSWI

Yahoo | March 9, 2023

Clearside Biomedical to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Thursday, March 9, 2023

ALPHARETTA, Ga., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2022 financial results will be reported on Thursday, March 9, 2023 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provi

Yahoo | February 23, 2023

Clearside Biomedical Announces Positive Data Presentations on CLS-AX OASIS Clinical Trial and Use of SCS Microinjector® Presented at the Angiogenesis and Macula Society Annual Meetings

- CLS-AX OASIS Results Show Favorable Safety Data, Durability and Biologic Effect Over 6 Months in Treatment-Experienced Anti-VEGF Sub-Responders - - SCS Microinjector® Featured in Favorable Data Presentations Related to Multiple Therapies in Clinical Development – ALPHARETTA, Ga., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announ

Yahoo | February 21, 2023

Read More 'CLSD' Stories Here

CLSD Price Returns

1-mo -11.11%
3-mo -7.14%
6-mo -13.33%
1-year -55.56%
3-year -32.90%
5-year -89.86%
YTD -7.14%
2022 -59.27%
2021 0.36%
2020 -5.52%
2019 171.03%
2018 -84.71%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7629 seconds.